Literature DB >> 29185196

ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.

Maryann Mazer-Amirshahi1, Andrew Stolbach2, Lewis S Nelson3.   

Abstract

Antidotal therapy is an essential component of poisoning management. In recent years, there have been unprecedented increases in the costs of antidotes. The American College of Medical Toxicology calls upon providers, hospitals, formularies pharmaceutical industry, government, insurance companies, and pharmacy benefit managers to adopt practices to ensure that antidotes are available to our patients and price are based on value and cost.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29185196      PMCID: PMC5962460          DOI: 10.1007/s13181-017-0639-z

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  8 in total

1.  Using market-exclusivity incentives to promote pharmaceutical innovation.

Authors:  Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  High-cost generic drugs--implications for patients and policymakers.

Authors:  Kathleen Uhl; John R Peters; Keith Flanagan
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

3.  Rising cost of antidotes in the U.S.: cost comparison from 2010 to 2015.

Authors:  Gregory A Heindel; Jeanette D Trella; Kevin C Osterhoudt
Journal:  Clin Toxicol (Phila)       Date:  2017-02-06       Impact factor: 4.467

4.  Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.

Authors:  Panos Kanavos; Alessandra Ferrario; Sotiris Vandoros; Gerard F Anderson
Journal:  Health Aff (Millwood)       Date:  2013-04       Impact factor: 6.301

Review 5.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Authors:  Aaron S Kesselheim; Jerry Avorn; Ameet Sarpatwari
Journal:  JAMA       Date:  2016 Aug 23-30       Impact factor: 56.272

6.  Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.

Authors:  Victoria Divino; Mitch DeKoven; Michael Kleinrock; Rolin L Wade; Satyin Kaura
Journal:  Health Aff (Millwood)       Date:  2016-09-01       Impact factor: 6.301

Review 7.  Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States.

Authors:  R C Dart; L R Goldfrank; P A Chyka; D Lotzer; A D Woolf; J McNally; W R Snodgrass; K R Olson; E Scharman; R J Geller; D Spyker; M Kraft; R Lipsy
Journal:  Ann Emerg Med       Date:  2000-08       Impact factor: 5.721

Review 8.  Why are cancer drugs so expensive in the United States, and what are the solutions?

Authors:  Hagop Kantarjian; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2015-03-16       Impact factor: 7.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.